CBA Annual Conference is Set to Promote Biopharmaceutical Partnership Across the Pacific.ROCKVILLE, Md. -- The Chinese Biopharmaceutical Association-USA (CBA See Capital Builder Account. ) announced today that its Annual Conference will be held in Rockville, Maryland Rockville is the county seat of Montgomery County, Maryland, United States. According to the 2006 census update, the city had a total population of 59,114, making it the second largest city in Maryland. , June 2-3, 2007. The theme of this year's CBA Annual Conference is Biopharmaceutical Development: From Discovery to Commercialization. The conference will virtually cover all critical areas in biopharmaceutical development. Over 20 experts from industry, academia and government agencies will share their vision, insight and experiences. CBA's Annual Conference, in its 12th year, will highlight steps critical to the success translation of a discovery to a commercial product. The gathering is specifically designed to provide an intimate setting for collaboration and exchange among companies who have cutting-edge discoveries and development both in the U.S. and in China. "This conference is designed to be a unique platform for building international collaborations and business partnerships into China, one of the world's fastest growing economies, and into the US, the largest economy in the world," said Dan Zhang, President, and Yuling Li, President-Elect of the Chinese Biopharmaceutical Association-USA (CBA). Conference program information includes: * Process Development and Manufacturing * From Discovery to Clinical Development * Toucan toucan (t  kăn`, t`kän), perching bird of the New World tropics, related to the woodpeckers. Forum on Biopharmaceutical Business in China
* Path to Regulatory Approval * Genome Integrity and Cancer (CBA-SCBA Joint Session) * Young Scientist Forum * Life of Seaturtles: The Hope and the Hype: Oversea Returnees and Chinese Science Keynote and Featured Speakers for the conference include: Natural Products: Past, Present, and Future Role in Drug Discovery John W. Daly, Ph.D., Scientist Emeritus, NIDDK NIDDK National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health, Member of National Academy of Sciences Clinical Research and Early Drug Development in Asia Paul Lietman, MD, Ph.D., Professor, Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. The Third Dimension of Growth Strategy for Global Biopharmaceuticals: Geographic Reach to China and Beyond Dr. Whaijen Soo, MD, Ph.D., Senior Vice President of Medical Research, BiogenIdec. Points to Consider for Expedient Completion of a GMP GMP (guanosine monophosphate): see guanine. Biologics Facility Robert J. Valdes, MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration , Associate Director, Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Inc. Single Use Technologies for Today's BioPharmaceutical Production Xuemin Liu, Ph.D., Marketing Manager, Pall Corporation Pall Corporation NYSE: PLL, formerly Micro Metallic Company, is an East Hills, New York based global business in the diverse field of filtration, separations and purification. Total revenues for fiscal 2006 were $2 billion, with over 11,000 employees and $56. Clinical trials in China by Small US Biotech Companies: Opportunities and Challenges Linda Powers, Managing Director, Co-founder, Toucan Capitals Preclinical Drug Discovery Services in China: Medicilon Experience Chun-Lin Chen, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Medicilon Inc. Regulation of Biotechnological/Biological Products in the United States of America UNITED STATES OF AMERICA. The name of this country. The United States, now thirty-one in number, are Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, Andrew Chang, Ph.D., Senior Director, PharmaNet Consulting The Pursuit of Success in the Chinese Biopharmaceutical Industry Jing jing (jing) [Chinese] one of the basic substances that according to traditional Chinese medicine pervade the body, usually translated as "essence"; the body reserves or constitutional makeup, replenished by food and rest, that supports Lou, Ph.D., CEO, 3Sbio Collaboration and Information Sharing to Translate Science into Applied and Marketable Technology Colonel Jayson Sawyer, Chief, Analysis and Assessment Team, Department of the Army Selection and Development of New Biologics for Clinical Development Adam Bell, Ph.D., Director, CoGenesys, Inc. The Story of a Small NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. Grant to a Multimillion Dollar Clinical Success Chun Li, Ph.D., Professor, University of Texas, M.D. Anderson Cancer Center Antibodomic Approach to Discover and Develop Novel Antibody Targets and Fully Human Antibody Leads Jian Ni, M.D., Ph.D., CEO & Chief Scientist, Human Antibodomics Inc. Haigui, What Do You Expect and What are You Expecting in China? An Pu Ruo, Renowned Novelist, VC Investor and Deal Maker The Hope and the Hype: Oversea Returnees and Chinese Science Shi-min Fang, Ph.D., President, New Threads Chinese Cultural Society For more information, please visit www.cba-usa.org or call Dr. Yali Fu at 240-351-7277. Attendance is limited, so please register early. Media is highly encouraged to attend. About CBA: The Chinese Biopharmaceutical Association (CBA) is a non-profit organization of professionals in the areas of bio-pharmaceutical research and technology development. It was established in the Spring of 1995 with its headquarters located in Maryland. The majority of CBA members are Chinese scientists, researchers, or professors working in government agencies, universities, research institutes, and biotechnology and pharmaceutical industries. Among them, many are doing pioneering research with the National Institutes of Health (NIH), and some are directly involved in the government regulatory process as officers of the Food and Drug Administration. CBA's Executive Committee consists of research, regulatory and management professionals representing all sectors of the bio-pharmaceutical research and development institutions as well as regulatory agencies. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion